Roche
A Leading Pharmaceuticals Pipeline

Dr. Guido Magni, Global Head of Medical Science

Lehman Brothers Healthcare Conference, Miami – March 2007

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com

Building on our current success to secure the future

Focused commercial and R&D efforts

Focus on medically differentiated products

	2001	2006
Top 10 as % of pharma sales	56 %	67 %
Key products % of pharma sales	27 %	59 %

Group products/ franchises > CHF 1 bn



2006 regulatory and R&D achievements to secure long term growth

- 20 approvals
- 18 filings (2 NMEs, 16 line extensions)
- 9 out of 10 pivotal phase III trials positive
- 12 phase III trials completed recruitment
- 12 phase III trials initiated



Key Development Projects

New R&D Model

Appendix

Roche key therapeutic areas

Current and future pillars of growth



Oncology: A leading phase III pipeline

Targeting main tumor types and use in early intervention

	ADJUVANT	MAINT.	1st LINE	2nd LINE
Filed or to file soon			Tarceva pancreatic Ca Avastin NSCLC Avastin mBC Xeloda gastric Ca Avastin mCRC 1st line ext. Avastin RCC Herceptin mBC combo hormonal Xeloda mCRC 1st line combo	Xeloda mCRC 2nd line combo
Ongoing	Xeloda adjuvant BC Xeloda adjuvant CC combo Avastin adjuvant CC Avastin adjuvant rectal Ca Tarceva adjuvant NSCLC	Tarceva & Avastin NSCLC maintenance MabThera iNHL maintenance	Avastin mBC 1st line ext. Avastin pancreatic Ca Avastin NSCLC 1st line ext. Avastin ovarian Ca MabThera 1st line CLL Herceptin gastric Ca Tarceva NSCLC 1st line Avastin & Herceptin mBC 1st line ext.	MabThera relapsed CLL Avastin prostate Ca Tarceva & Avastin NSCLC 2nd line Avastin mBC 2nd line
To start soon	Avastin adjuvant NSCLC Avastin adjuvant BC			

The future: Combination of targeted therapies
Roche in lead

	NSCLC			Breast Cancer				Pancreatic
Study	ATLAS (Phase III)	BETALung (Phase III)	Phase II	AVEREL (Phase III)	Pegram (Phase II)	Phase III	Phase II	AVITA (Phase III)
Patient population	1st line maintenance non-squam.	2nd line	2nd line	1st line	1st line	Adjuvant	2nd line	1st line
Treatment regimen	CT + Avastin -> Avastin ± Tarceva	Tarceva ± Avastin	Avastin + Tarceva vs. Avastin + CT vs. CT	Herceptin + Taxotere ± Avastin	Herceptin + Avastin	Herceptin + Avastin tbd	Herceptin + Omnitarg	Gemcita-bine/ Tarceva ± Avastin
Status	Started Q4'05	Started Q2'05	Presented ASCO'06 SABC '06	Started Q3 '06	Presented SABC '06	Planned	Ongoing	Started H1'06

Potential patient benefits
- higher efficacy
- individualized treatment
- better tolerability

Roche setting the standard of care in combined targeted therapies

Avastin: Ready for European launch in lung and breast cancer

Non-small cell lung cancer 1st line

- **E4599**
  - Paclitaxel/carboplatin +/- Avastin
  - Median OS improved by 27 percent
- **"Avastin in Lung" ***
  - Gemcitabine/cisplatin +/- Avastin
  - PFS significantly prolonged
  - Part of EU registration

US: Approved for NSCLC in Oct. '06
EU: filed for NSCLC in August '06

Metastatic breast cancer 1st line

- **E2100**
  - Randomized, controlled, multi-centre study (722 women)
  - Paclitaxel +/- Avastin
  - Doubling of PFS from 6.7 to 13.3 m.
- **Further trials ongoing**
  - AVADO (Taxotere +/- Avastin)
  - RIBBON-1 (various chemos +/- Av.)
  - AVEREL (Taxotere + Herceptin +/- Avastin, in HER2+ patients)

US: FDA – resubmission in mid-'07
EU: CHMP positive recommendation

* Formerly called AVAiL

Oncology: early stage clinical pipeline

Next generation products emerging

Omnitarg (pertuzumab)

- Binds to HER2 receptor and inhibits its ability to pair with HER family members
- **Ovarian cancer (phase II)**
  - GNE trial: in platinum-resistant ovarian cancer, encouraging results
  - Roche trial: in platinum-sensitive ovarian cancer ongoing, data by early 2008
- **Breast cancer (phase II)**
  - In Herceptin pre-treated patients, data in 2007

Phase II data available 2007

Epothilones

- Inhibit cell division with a mechanism similar to taxanes
- Potential to overcome multi-drug resistance, synergistic with other therapies
- High level of tolerability
- Collaboration with Kosan
- **R1645**
  - Second generation epothilone
  - Two phase I trials completed
  - Antitumor activity and good tolerability

Phase II to start 2007

Roche in rheumatoid arthritis / autoimmune

Building a new therapeutic franchise

MabThera

- Launched in RA anti-TNFα inadequate responders in US and EU
- Filing for RA in DMARD IR in 2008

Actemra

- Filed in Japan
- Broad international phase III program
- Global filing in 2007

CellCept

- Phase III in Lupus Nephritis (LN); recruitment completed, filing 2007

MabThera

- Phase III in LN, ANCA ass. vasculitis and SLE ongoing

Ocrelizumab

- Phase II trial in RA met primary and secondary endpoints, presented at ACR '06
- Phase III program in RA initiated
- Trials in LN and SLE to start in 2007

R1503 (p38 kinase inhibitor)

- In Phase II in RA
- Data in 2007

In phase 1

- 2 compounds for autoimmune diseases

7 phase III projects

1 phase II projects

Actemra

Potential to become a significant new RA treatment

First-in-class agent

- Humanized monoclonal antibody blocking the activity of IL-6
- Conclusions from phase III Jap trials
  - Impressive efficacy in DMARD inadequate responders
  - Effective as monotherapy
  - Well tolerated

Filed in Japan in April 2006

Large international phase III program

- 5 registration trials (>4'000 patients) - recruitment completed
- Mono and combo therapy
- Patient populations studied:
  - MTX inadequate responders
  - DMARD inadequate responders
  - TNFα inadequate responders
  - MTX naïve patients
- **First trial (OPTION) met primary endpoint – submitted for EULAR**
- Further clinical data during 2007

Global filing in 2007

Emerging multiple sclerosis portfolio

New approaches to MS therapy – multiple opportunities

MabThera (anti CD-20)

- Phase II (HERMES) in RRMS met primary endpoints
- Data to present at AAN '07
- Phase II/III in PPMS (OLYMPUS) – results in H1 2008

Ocrelizumab (hum. anti CD-20)

- Phase II / III in RRMS in preparation

R1295

- Orally active
- Phase II in preparation

R3477 (S1P1 receptor agonist)

- Phase I- joint development with Actelion
- Inhibits migration and recirculation of lymphocytes from lymph nodes
- Orally active
- In development for multiple autoimmune disorders, including MS

2 phase III project (ongoing, in preparation)

2 phase I projects

Roche in metabolic / cardiovascular diseases

Major decision points within the near future

R1583 (GLP-1)
- Phase II data (immediate release) presented at ADA'06
- Phase II (sustained release) to initiate early '07
- Filing 2010

R1440 (GKA)
- Phase II started Q4'05
- First phase II data available 2007
- Filing 2009

R1439
- Dual PPAR (α/γ) agonist
- Phase II initiated in Q4 '06
- Filing post 2010

In phase I
- 3 compounds in development for metabolic/ CV diseases

4 phase II projects

3 phase I projects

Cardiovascular diseases / dyslipidemia

R1658 – CETP Inhibitor

- In-licensed from Japan Tobacco
- Raises HDL ('good') cholesterol levels
- Phase II program ongoing
  - Two efficacy trials in combination with a statin completed
  - Safety trial to be completed by mid-2007
- Preliminary results
  - Up to 900 mg daily is well-tolerated, with a similar overall safety profile to placebo
  - **Encouraging efficacy data**
  - **No increase in blood pressure**

Go / no go decision for phase III in 2007

Roche in virology

Building on our leading position in Hepatitis C

R1626 (Polymerase inhibitor)
- Phase II ongoing
- Promising phase I data presented at EASL and AASLD in 2006
- Filing post 2010

R7227 (Protease inhibitor)
- In phase I (initiated January 2007)
- Licensed from InterMune

R7128 (Polymerase inhibitor)
- In phase I
- Licensed from Pharmasset

R7025 (next generation IFN)
- Next generation pegylated interferon alpha
- In phase I
- Licensed from Maxygen

1 phase II project
3 phase I projects

Strong clinical news-flow in H1'07

Data submitted to upcoming medical meetings

Product	Trial	Phase	Indication	Congress
MabThera	HERMES	II	RRMS	AAN, April 2007
Avastin	AVOREN	III	1st line RCC	ASCO, June 2007
Avastin	"Avastin in Lung"	III	1st line NSCLC	ASCO, June 2007
Avastin/Xeloda	NO16966	III	1st line mCRC	ASCO, June 2007
Xeloda	NO16967	III	2nd line mCRC	ASCO, June 2007
Omnitarg		II	Platinum-resistant ovarian Ca	ASCO, June 2007
Actemra	OPTION	III	RA MTX inadequate responders	EULAR, June 2007

Roche

Key Development Projects

New R&D Model

Appendix

New pharma model: Disease Biology Areas (DBAs)

Alignment and focus

Roche

Disease Biology Areas (DBAs)

Idea ⟷ Market



- Initial focus on five DBAs
- Decisions made by Disease Biology Leadership Teams (DBLTs) against measurable metrics
- **Up to Proof of Concept:** DBLTs manage compound progression within respective DBA
- **After Proof of Concept:** DBLTs responsible for conducting scientific/ medical reviews and providing options to Pharma Leadership Team

- ➢ **Clear focus**
- ➢ **More independent and flexible disease areas**
- ➢ **Faster and simpler decision processes**

Streamlined decision making throughout drug lifecycle

Simpler, more transparent oversight



Summary

Building additional value propositions

- Oncology – worldwide leadership and continuing to expand
- Anemia – filed globally/ preparing for launch
- Autoimmune diseases/ RA/ MS – a new growth area
- Metabolic disease – an opportunity for future growth shaping up
- HCV – framing the next standard of therapy

We Innovate Healthcare

Key Development Projects

New R&D Model

Appendix

Roche R&D pipeline today

Roche

phase I (25 NMEs + 2 AIs)		phase II (18 NMEs + 9 AIs)		phase III (3 NMEs + 35 AIs)			Registration (2 NMEs + 7 AIs)		
R1295	MS	R1558	bacterial infections	R1569	Actemra	RA	R744	Mircera	renal anaemia
R3477	autoimmune diseases	R1503	RA	R1594	Ocrelizumab	RA	CHU	Antevas	subarach haemorr
R3421	AI / transplant	R1439	type 2 diabetes	CHU	ED-71	osteoporosis	R597	Herceptin	mBC combo hormonal
R1511	type 2 diabetes	R1440	type 2 diabetes	R1569	Actemra	sJIA	R435	Avastin	NSCLC 1st line
R1579	type 2 diabetes	R1583	type 2 diabetes	R99	CellCept	lupus nephritis	R435	Avastin	mBC combo Taxol 1st
R1663	anticoagulant	R1658	dyslipidemia	R99	CellCept	pemphigus vulgaris	R1415**	Tarceva	pancreatic ca
R1646	overactive bladder	R1273	Omnitarg ovarian cancer	R105	MabThera	RA DMARD inad resp	R340	Xeloda	gastric cancer
R1450	Alzheimer's	R1492	solid tumors	R105	MabThera	CLL 1st line	CHU	Epogin	cancer anaemia
R1678	schizophrenia	R667	emphysema	R105	MabThera	CLL relapse	CHU	Sigmart	acute heart fail
R7118	schizophrenia	R1626	HCV	R105	MabThera	iNHL maint 1st line			
R1647	depression	GEN	diabetic foot ulcers	R1415	Tarceva	NSCLC maint 1st			
R7090	anxiety	GEN	NHL	R1415	Tarceva	adj NSCLC			
R547	solid tumors	GEN	growth hormone deficiency	R1415+R435	Tarceva+Avastin	NSCLC 2nd line			
R1507	solid tumors	ISO	renal transplant	R1415+R435	Tarceva+Avastin	NSCLC 1st line maint			
R1530	solid tumors	ARQ	solid tumors	R340	Xeloda	mCRC combo 1st			
R1645	solid tumors	CHU	gastroparesis / IBS	R340	Xeloda	mCRC combo 2nd			
R7204	malignant melanoma	CHU	post-hepatectomy	R340	Xeloda	adj CC combo oxaliplatin			
R7025	HCV	GEN	asthma	R340	Xeloda	adj CC combo Avastin			
R7227 *	HCV	R744	CERA cancer anaemia	R340	Xeloda	adj BC			
R7128	HCV	R435	Avastin NSCLC squamous	R435	Avastin	adj CC			
GEN	malignant melanoma	R435	Avastin NSCLC mCNS treat	R435	Avastin	pancreatic cancer			
GEN	cancer	R1594	Ocrelizumab RRMS	R435	Avastin	RCC			
GEN	mBC	R1273	Omnitarg mBC	R435	Avastin	prostate ca			
MEM	Alzheimer's	GEN	Avastin adj BC HER2-	R435	Avastin	ovarian cancer 1st line			
CHU	CRC	GEN	Avastin glioblastoma recurr	R435	Avastin	mCRC 1st extension			
R127	valganciclovir ulcerat colitis	GEN	Avastin ovarian cancer 2nd line	R435	Avastin	mBC combo Taxotere 1st			
GEN	CLL / MM	GEN	Lucentis diabetic macular edema	R435	Avastin	BC combo nonTaxanes 1st			
				R435	Avastin	mBC combo Herceptin 1st			
				R597	Herceptin	gastric ca			
				R127	Valcyte	CMV extension			
				GEN	Avastin	GIST recurr			
				GEN	Avastin	adj rectal cancer			
				GEN	Avastin	mBC 2nd line			
				GEN	MabThera	lupus nephritis			
				GEN	MabThera	PPMS			
				GEN	MabThera	ANCA ass vascul			
				GEN	MabThera	SLE			
				GEN	Xolair	pediatric asthma			

* Ph1 initiated January 2007

** Approved EU January 2007

NME (New Molecular Entity)
- R Roche managed projects
- A Opt-in Opportunities
- A Participations

AI (Additional Indication)
- R Roche managed projects
- A Opt-in Opportunities
- A Participations

CHU Chugai
GEN Genentech
ARQ ArQule
ISO Isotechnika
MEM Memory

Status as of December 31, 2006

Avastin: Building standard of care, sustaining leadership

Effectively maximizing an asset

Roche

Main Indication		Status	
NSCLC	1st line non-squamous	Avastin in Lung*	Recr. completed, Final analysis H1'07
		ATLAS	Initiated Q4'05
	1st line squamous	AVASQ	Initiated Q3'06
		BRIDGE	Pilot initiated Q2'06
	2nd line	BETA Lung	Initiated Q2'05
Adjuvant NSCLC		ECOG 1505	To initiate H1'07
mBC	1st line HER2-negative	AVADO	Recr. to complete H1'07
		RIBBON-1	Initiated Q4'05, Global recruitment launched
	1st line HER2-positive	AVEREL	Initiated Q3'06
	2nd line	RIBBON-2	Initiated Q1'06
Adjuvant BC	HER2-negative	E2104	Pilot initiated Q4'05, Analysis Q1'07
		E5103	To initiate 2007
		BO20289	To initiate 2007
	HER2-positive	006R/B-31R	In preparation

Main Indication		Status	
mCRC	1st line	NO16966	Positive results Q3'06, Filing H1'07
Adjuvant CC		AVANT	Recr. to complete H1'07
		NSABP C-08	Recr. completed
Adjuvant rectal Ca		E5204	Initiated Q1'06
RCC	1st line	AVOREN	Positive results Q4'06, Filing 2007
		CALGB 90206	Awaiting results
Pancreatic Ca	1st line	AVITA	Recr. completed
Ovarian Ca	1st line	GOG 218	Initiated Q3'05
		ICON7	Initiated Q4'06
	2nd line	GOG 213	In preparation
Prostate Ca	Hormone refractory	CALGB 90401	Initiated Q2'05

* Formerly called AVAIL

Xeloda/ Tarceva/ MabThera/ Herceptin:
Maximizing across the portfolio

Main Indications			Status
Xeloda			
Adjuvant CC	Combo Avastin	**AVANT**	Recr. to complete H1'07
	Combo oxaliplatin	**NO16968**	Recr. completed, Final analysis end '07/early '08
Adjuvant BC		**NO 17629**	Recr. completed
Tarceva			
NSCLC 1st line maintenance	Combo chemotherapy	**SATURN**	Initiated Q4'05, Recr. to complete '07
		TITAN	Initiated Q4'05, Recr. to complete '07
	Combo Avastin	**ATLAS**	Initiated Q4'05
NSCLC 2nd line	Combo Avastin	**BETA Lung**	Initiated Q2'05
Adjuvant NSCLC		**RADIANT**	Initiated Q3'06
MabThera			
NHL maintenance 1st line	After MabThera induction	**PRIMA**	Initiated Q1'06, Recr. to complete H1'07
CLL 1st line		**ML17102**	Recr. completed
CLL relapsed		**REACH**	Recr. to complete end '07
Herceptin			
Gastric Ca		**ToGA**	Initiated Q3'05, Recr. to complete H2'07
Adjuvant BC	1yr vs. 2yrs treatment	**HERA**	Final analysis 2008/2009

Rheumatoid Arthritis/ Auto Immune
Major indications in phase III development

Main Indication			Status
Rheumatoid arthritis			
MabThera	MTX - inadequate responders	**SERENE, SUNRISE MIRROR**	Recr. completed
	MTX -naive	**IMAGE**	Initiated Q1'06
	Combo Enbrel	**TAME**	Initiated Q2'06
Actemra	MTX (DMARD) - inadequate resp. or -naive	**OPTION, TOWARD, AMBITION**	Recr. completed, Final analysis by mid '07 (OPTION January '07)
	Anti-TNF inadequate resp.	**RADIATE**	Recr. completed, Final analysis by mid '07
	MTX inadequate responders	**LITHE**	Recr. completed
Ocrelizumab	MTX inadequate responders	**Phase III**	Initiated Q4'06
	Anti-TNF inadequate responders	**Phase III**	To initiate H1'07
	X-ray study	**Phase III**	To initiate H1'07
ANCA ass. vasculitis			
MabThera		**RAVE**	Initiated Q4'04

Main Indication			Status
Multiple sclerosis			
MabThera	PPMS	**OLYMPUS**	Recr. completed Q4'05
	RRMS	**HERMES**	Met primary endpoint Q3'06, To be presented at AAN'07
Ocrelizumab	RRMS	**Phase II or III**	In discussion
Lupus nephritis			
MabThera		**LUNAR**	To complete recr. H2'07
Ocrelizumab		**Phase III**	To initiate Q2'07
CellCept		**Phase III**	Recr. completed, Results (induction phase) H1'07
SLE			
MabThera		**EXPLORER**	To complete recr. Q1'07
Ocrelizumab		**Phase III**	To initiate in Q2'07

Metabolic and vascular diseases
Major decision points in 2007

Main Indications		Status
Type 2 Diabetes		
R1440 (GKA)	Phase II	Initiated Q4'05 First phase II data available 2007 Filing 2009
R1583 (GLP-1)	Phase II immediate release formulation	Presented at ADA'06
	Phase II sustained release formulation	To initiate early 2007
R1439 (PPAR α/γ)	Phase II	Initiated Q4'06
R1579	Phase I	Ongoing
R1511	Phase I	Ongoing
Dyslipidemia		
R1658 (JTT-705)	Phase II efficacy	Encouraging data obtained H1'06
	Phase II safety	Results by mid'07 Go/ No go decision for phase III in 2007 Filing 2010

2006: Approvals
20 Roche Group approvals in various franchises

Product	Indication	Region
Avastin	2nd line colorectal cancer	US
Avastin	1st line advanced NSCLC	US
Herceptin	Adjuvant breast cancer	US, EU
MabThera	Maintenance treatment iNHL relapsed	EU
Rituxan	1st line iNHL	US
Rituxan	1st line aNHL	US
Rituxan	iNHL treatment following 1st-line CVP	US
Tarceva*	Pancreatic cancer	EU
Femara	Breast cancer	Japan
MabThera/Rituxan	Rheumatoid arthritis (anti-TNF inadequate responders)	US, EU
Bonviva/Boniva	Osteoporosis (IV)	US, EU
NeoRecormon*	Once-weekly dosing	EU
Tamiflu	Pediatric influenza prophylaxis	EU
Lucentis	AMD	US
Invirase	HIV/AIDS (500mg)	Japan
Pegasys/Copegus*	HCV	Japan
Epogin	Anemia in premature infants	Japan

* Approved in January '07

2006: Filings

18 Roche Group filings

Product	Indication	Region
Avastin	1st line advanced NSCLC	US, EU
Avastin	1st line metastatic breast cancer	US, EU
Avastin	Advanced or recurrent colorectal cancer	Japan
Herceptin	Adjuvant breast cancer	US, EU, Japan
Herceptin	Metastatic BC, combo hormonal	EU
Herceptin	Adjuvant BC, node +ve and -ve	US
Rituxan	1st line iNHL	US
Rituxan	iNHL treatment following 1st line CVP	US
Tarceva	NSCLC	Japan
Xeloda	Gastric cancer	EU
Xeloda	Adjuvant colon cancer	Japan
Actemra	Rheumatoid arthritis / sJIA	Japan
Mircera	Renal anemia	US, EU

2006: Major phase III data

9 positive pivotal trials for future growth

Product	Indication	Study	Comment
Avastin / Xeloda	1st line metastatic CRC combo	NO16966	Final
Avastin	Advanced renal cell carcinoma	AVOREN	Final PFS, Top-line
Herceptin	Metastatic BC, combo hormonal	TAnDEM	Final
Xeloda	Gastric and oesophagogastric cancer	ML17032, REAL2	Final
Xeloda	2nd line metastatic CRC combo	NO16967	Final, Top-line
Actemra	Rheumatoid arthritis	SATORI	Final
Mircera	Renal anemia (correction)	AMICUS, ARCTOS	Final

2006: Additional phase III data

5 major follow-up analyses positive

Product	Indication	Study (Follow-up)	Comment
Herceptin	Adjuvant BC	HERA (23 months)	Approved EU and US
Herceptin	Adjuvant BC	BCIRG 006 (36 months)	Approved EU and US
MabThera	iNHL 1st line	RCVP (53 months)	Approved EU and US
MabThera	RA (TNF IR)	REFLEX (12 months)	Approved EU and US
Boniva	Osteoporosis	MOBILE (36 months)	Approved EU and US

2006: Phase III recruitment completed

Product	Indication	Study
Avastin	1st line advanced NSCLC	Avastin in Lung
Avastin	Adjuvant colon cancer	NSABP CO-8
Avastin	Pancreatic cancer	AVITA
Actemra	Rheumatoid arthritis	OPTION, LITHE, TOWARD, RADIATE, AMBITION
MabThera/ Rituxan	Rheumatoid arthritis (DMARD inadequate responders)	SERENE, SUNRISE, MIRROR
CellCept	Lupus nephritis	

2006: Phase III trials initiated

Increasing commitment in RA / AI

Product	Indication	Study
Avastin	1st line mBC	AVADO
Avastin	2nd line mBC	RIBBON-2
Avastin/ Herceptin	1st line mBC (HER2-pos)	AVEREL
Avastin	1st line ovarian cancer	ICON7
Avastin/ Tarceva	1st line NSCLC maintenance	ATLAS
Avastin	Adjuvant rectal cancer	E5204
MabThera/ Rituxan	Rheumatoid arthritis (DMARD inadequate responders)	IMAGE, MIRROR, SUNRISE
MabThera/ Rituxan	Lupus nephritis	LUNAR
Ocrelizumab	Rheumatoid arthritis (DMARD inadequate responders)	
Valcyte	Transplantation	

2006: Phase II data

Building the growth blocks for 2010 onwards

Product	Indication
Avastin + Herceptin	1st line mBC (Her2-pos)
Avastin + Tarceva	2nd line NSCLC
Omnitarg	Platinum-resistant ovarian cancer
MabThera/ Rituxan	Relapsing-remittent multiple sclerosis
Ocrelizumab	Rheumatoid arthritis
R1658 (CETP)	Dyslipidemia
R1583 (GLP-1)	Type II diabetes (immediate release formulation)


Roche
We Innovate Healthcare